Ohio State University has brought on a former biopharma executive to lead its cancer-specific Drug Development Institute with the goal of enhancing and optimizing promising oncology research for potential deal-making before the formal tech transfer process begins.
Jeffrey Patrick became director of the university's cancer-focused Drug Development Institute in February, bringing a varied biopharma background, including most recently the role of chief scientific officer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?